The Moderna vaccine has a 94.5% efficiency, according to the first results of the pharmaceutical company. It is the second company to announce that its dose is equal to or greater than 90%, as confirmed by the American pharmaceutical company Pfizer.
“Essay has met the pre-specified statistical criteria in the protocol of the efficacy study, with a vaccine efficacy of 94.5% ”, announces Moderna in a statement. This study, known as the COVE study, involved more than 30,000 people in the US. And it’s being done in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Institute.
“The first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, which resulted in a point estimate of the efficacy of the vaccine of 94.5% ”, he explains the company.
The 95 cases of coronavirus included 15 older adults (over 65 years of age) and 20 participants who identified as belonging to diverse communities (including 12 Hispanic / Latino, 4 Black / African American, 3 Asian American, and 1 multiracial).
500 million doses by 2021
“This is a crucial moment in the development of our COVID-19 vaccine candidate. Since the beginning of January, we have been pursuing this virus with the intention of protecting as many people as possible around the world. All along we have known that each day is important. This positive interim analysis from our phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, ”said Stéphane Bancel, CEO of Moderna.
By the end of 2020, the company expects to have approximately 20 million ready doses and estimates that it will be able to manufacture 500 million to 1 billion doses globally in 2021.